Agilent Technologies, Inc. (NYSE:A) Shares Sold by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. reduced its stake in Agilent Technologies, Inc. (NYSE:A - Free Report) by 40.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,110 shares of the medical research company's stock after selling 12,496 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in Agilent Technologies were worth $2,119,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Redwood Park Advisors LLC purchased a new position in shares of Agilent Technologies in the 4th quarter valued at $27,000. Lee Danner & Bass Inc. acquired a new position in Agilent Technologies in the fourth quarter valued at $29,000. Whipplewood Advisors LLC grew its holdings in shares of Agilent Technologies by 286.2% during the first quarter. Whipplewood Advisors LLC now owns 251 shares of the medical research company's stock worth $29,000 after purchasing an additional 186 shares during the last quarter. Sunbelt Securities Inc. grew its holdings in shares of Agilent Technologies by 640.0% during the fourth quarter. Sunbelt Securities Inc. now owns 222 shares of the medical research company's stock worth $30,000 after purchasing an additional 192 shares during the last quarter. Finally, Opal Wealth Advisors LLC acquired a new stake in shares of Agilent Technologies during the first quarter worth about $31,000.

Insider Buying and Selling at Agilent Technologies

In other Agilent Technologies news, Director Daniel K. Podolsky sold 1,819 shares of the company's stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $116.46, for a total value of $211,840.74. Following the sale, the director now owns 35,737 shares of the company's stock, valued at $4,161,931.02. This represents a 4.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Leerink Partners raised their price target on Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research note on Friday, May 30th. UBS Group decreased their price objective on Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating for the company in a report on Thursday, May 29th. Barclays decreased their price target on shares of Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. JPMorgan Chase & Co. decreased their target price on shares of Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a research note on Thursday, May 29th. Finally, Wells Fargo & Company dropped their price target on Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating on the stock in a research report on Thursday, April 17th. Eight investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Agilent Technologies has a consensus rating of "Hold" and a consensus price target of $140.15.

Agilent Technologies Stock Up 0.1%

Agilent Technologies stock opened at $115.61 on Monday. The stock's 50 day moving average price is $110.67 and its 200 day moving average price is $124.50. The company has a market cap of $32.84 billion, a PE ratio of 28.55, a price-to-earnings-growth ratio of 3.51 and a beta of 1.23. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.09 and a quick ratio of 1.60. Agilent Technologies, Inc. has a 1-year low of $96.43 and a 1-year high of $153.84.

Agilent Technologies (NYSE:A - Get Free Report) last issued its earnings results on Wednesday, May 28th. The medical research company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.26 by $0.05. The company had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.63 billion. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. The business's revenue was up 6.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.22 EPS. On average, sell-side analysts predict that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 23rd. Shareholders of record on Tuesday, July 1st will be issued a $0.248 dividend. This represents a $0.99 annualized dividend and a yield of 0.86%. The ex-dividend date is Tuesday, July 1st. Agilent Technologies's dividend payout ratio (DPR) is 24.44%.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.